Starting the year smarter
To start the year right, Fred Hutch scientists, providers and a patient advocate share tips to help readers keep up with the deluge of health and science information.
Related Articles
BTK Degraders Look to Fill Unmet Need for Patients With Pretreated B-Cell Malignancies
Michael T. Tees, MD, MPH, describes how BTK degraders represent a promising class of agents, highlighting the agent AC676 that is currently under evaluation.
Integrating PAP into Comprehensive Cancer Care for Mental Health
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
The case of an adult patient with a recurrent medulloblastoma is presented, that showed a 1-year-long benefit with second-line vismodegib, and where serial
How to treat MCL that is refractory to BTK inhibitors
During the Lymphoma Hub Steering Committee meeting, Martin Dreyling, Ludwig-Maximilians-Universität, Munich, DE, chaired a discussion on, How to treat MCL that is refractory to BTK…
VIDA
VIDA postdoctoral programme represents the perfect environment for the professional development of postdoctoral fellows in the cancer research & Oncology fields, expanding their future opportunities…
ELN 2024 recommendations: Genetic risk stratification in patients with AML receiving less-intensive therapies
Dohner et al. recently published ELN 2024 genetic risk classification for patients with AML receiving less-intensive therapies in Blood.
FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or Metastatic Gastric/GEJ Cancer
The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification
This cohort study examines whether there is an association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification in men with grade…
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study
The negative patient-reported effects associated with a CSD result from MCED testing were small and returned to baseline within 12 months for participants with or…
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
PURPOSEIn patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab…
